6q deletion detected by fluorescence in situ hybridization using bacterial artificial chromosome in chronic lymphocytic leukemia

European Journal of Haematology

Volumn 91, Issue 1, 2013, Pages 10-19

  Dalsass, Alessia ^a   Mestichelli, Francesca ^a   Ruggieri, Miriana ^a   Gaspari, Paola ^a   Pezzoni, Valerio ^a   Vagnoni, Davide ^a   Angelini, Mario ^a   Angelini, Stefano ^a   Bigazzi, Catia ^a   Falcioni, Sadia ^a   Troiani, Emanuela ^a   Alesiani, Francesco ^b   Catarini, Massimo ^c   Attolico, Immacolata ^d   Scortechini, Ilaria ^e   Discepoli, Giancarlo ^e   Galieni, Piero ^a  

^a SC Ematologia Ospedale C G Mazzoni   (Italy)

^b Day Hospital Oncologia Ematologia Ospedale B Eustacchio   (Italy)

^c Ospedale Generale Provinciale   (Italy)

^d SAN CARLO HOSPITAL   (Italy)

^e OSPEDALI RIUNITI   (Italy)

Author keywords

6q deletion; Chronic lymphocytic leukemia; Fluorescence in situ hybridization

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; INTERLEUKIN 2;

ADULT; AGED; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL NUCLEUS; CHROMOSOME 6Q; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CYTOGENETICS; DNA PROBE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC RISK; HUMAN; MAJOR CLINICAL STUDY; MALE; METAPHASE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CHROMOSOME DELETION; CHROMOSOME MAPPING; CHROMOSOMES, ARTIFICIAL, BACTERIAL; CHROMOSOMES, HUMAN, PAIR 6; FEMALE; HUMANS; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; OLIGONUCLEOTIDES; PROGNOSIS; TIME FACTORS;

EID: 84879462842     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12115     Document Type: Article

References (45)

1. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-7.
2. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-54.
3. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, Döhner K, Bentz M, Lichter P. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-6.
4. Kröber A, Seiler T, Benner A, Bullinger L, Brückle E, Lichter P, Döhner H, Stilgenbauer S. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002;100:1410-6.
5. Juliusson G, Gahrton G. Cytogenetics in CLL and related disorders. Baillieres Clin Haematol 1993;6:821-48.
6. Finn WG, Kay NE, Kroft SH, Church S, Peterson LC. Secondary abnormalities of chromosome 6q in B-cell chronic lymphocytic leukemia: a sequential study of karyotypic instability in 51 patients. Am J Hematol 1998;59:223-9.
7. Cuneo A, Rigolin GM, Bigoni R, et al. Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis. Leukemia 2004;18:476-83.
8. Stilgenbauer S, Bullinger L, Benner A, Wildenberger K, Bentz M, Döhner K, Ho AD, Lichter P, Döhner H. Incidence and clinical significance of 6q deletions in B cell chronic lymphocytic leukemia. Leukemia 1999;13:1331-4.
9. Méhes G. Chromosome abnormalities with prognostic impact in B-cell chronic lymphocytic leukemia. Pathol Oncol Res 2005;11:205-10.
10. Gérard B, Cavé H, Guidal C, Dastugue N, Vilmer E, Grandchamp B. Delineation of a 6 cM commonly deleted region in childhood acute lymphoblastic leukemia on the 6q chromosomal arm. Leukemia 1997;11:228-32.
11. Merup M, Moreno TC, Heyman M, et al. 6q deletions in acute lymphoblastic leukemia and non-Hodgkin's lymphomas. Blood 1998;91:3397-400.
12. Offit K, Parsa NZ, Gaidano G, Filippa DA, Louie D, Pan D, Jhanwar SC, Dalla-Favera R, Chaganti RS. 6q deletions define distinct clinico-pathologic subsets of non-Hodgkin's lymphoma. Blood 1993;82:2157-62.
13. Amiel A, Mulchanov I, Elis A, Gaber E, Manor Y, Fejgin M, Lishner M. Deletion of 6q27 in chronic lymphocytic leukemia and multiple myeloma detected by fluorescence in situ hybridization. Cancer Genet Cytogenet 1999;112:53-6.
14. Walker GJ, Palmer JM, Walters MK, Hayward NK. A genetic model of melanoma tumorigenesis based on allelic losses. Genes Chromosomes Cancer 1995;12:134-41.
15. Noviello C, Courjal F, Theillet C. Loss of heterozygosity on the long arm of chromosome 6 in breast cancer: possibly four regions of deletion. Clin Cancer Res 1996;2:1601-6.
16. Hyytinen ER, Saadut R, Chen C, Paull L, Koivisto PA, Vessella RL, Frierson HF Jr, Dong JT. Defining the region(s) of deletions at 6q16-q22 in human prostate cancer. Genes Chromosomes Cancer 2002;34:306-12.
17. Sandhu AK, Hubbard K, Kaur GP, Jha KK, Ozer HL, Athwal RS. Senescence of immortal human fibroblasts by the introduction of normal human chromosome 6. Proc Natl Acad Sci USA 1994;91:5498-502.
18. Theile M, Seitz S, Arnold W, et al. A defined chromosome 6q fragment (at D6S310) harbors a putative tumor suppressor gene for breast cancer. Oncogene 1996;13:677-85.
19. Mayr C, Speicher MR, Kofler DM, Buhmann R, Strehl J, Busch R, Hallek M, Wendtner CM. Chromosomal translocations are associated with, poor prognosis in chronic lymphocytic leukemia. Blood 2006;107:742-51.
20. Dicker F, Schnittger S, Haferlach T, Kern W, Schoch C. Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: a study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood 2006;108:3152-60.
21. Haferlach C, Dicker F, Schnittger S, Kern W, Haferlach T. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia 2007;21:2442-51.
22. Haferlach C, Rieder H, Lillington DM, Dastugue N, Hagemeijer A, Harbott J, Stilgenbauer S, Knuutila S, Johansson B, Fonatsch C. Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes. Genes Chromosomes Cancer 2007;46:494-9.
23. Buhmann R, Kurzeder C, Rehklau J, Westhaus D, Bursch S, Hiddemann W, Haferlach T, Hallek M, Schoch C. CD40L stimulation enhances the ability of conventional metaphase cytogenetics to detect chromosome aberrations in B-cell chronic lymphocytic leukaemia cells. Br J Haematol 2002;118:968-75.
24. Herholz H, Kern W, Schnittger S, Haferlach T, Dicker F, Haferlach C. Translocations as a mechanism for homozygous deletion of 13q14 and loss of the ATM gene in a patient with B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet 2007;174:57-60.
25. Mitelman F, ed. ISCN 1995: Guidelines for Cancer Cytogenetics, Supplement to: An International System for Human Cytogenetic Nomenclature. Basel: S. Karger; 1995:1-110.
26. Sherratt T, Morelli C, Boyle JM, Harrison CJ. Analysis of chromosome 6 deletions in lymphoid malignancies provides evidence for a region of minimal deletion within a 2-megabase segment of 6q21. Chromosome Res 1997;5:118-24.
27. Offit K, Louie DC, Parsa NZ, Filippa D, Gangi M, Siebert R, Chaganti RS. Clinical and morphologic features of B-cell small lymphocytic lymphoma with del(6)(q21q23). Blood 1994;83:2611-8.
28. Guan XY, Horsman D, Zhang HE, Parsa NZ, Meltzer PS, Trent JM. Localization by chromosome microdissection of a recurrent breakpoint region on chromosome 6 in human B-cell lymphoma. Blood 1996;88:1418-22.
29. Zhang Y, Weber-Matthiesen K, Siebert R, Matthiesen P, Schlegelberger B. Frequent deletions of 6q23-24 in B-cell non-Hodgkin's lymphomas detected by fluorescence in situ hybridization. Genes Chromosomes Cancer 1997;18:310-3.
30. Jackson A, Carrara P, Duke V, Sinclair P, Papaioannou M, Harrison CJ, Foroni L. Deletion of 6q16-q21 in human lymphoid malignancies: a mapping and deletion analysis. Cancer Res 2000;60:2775-9.
31. Muñoz L, Lasa A, Carricondo MT, Hernàndez C, Ubeda J, Nomdedèu JF. Comparative analyses of ZAP-70 expression and Ig VH mutational status in B-cell chronic lymphocytic leukemia. Cytometry B Clin Cytom 2007;72:96-102.
32. Schroers R, Griesinger F, Trümper L, Haase D, Kulle B, Klein-Hitpass L, Sellmann L, Dührsen U, Dürig J. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. Leukemia 2005;19:750-8.
33. Guarini A, Gaidano G, Mauro FR, et al. Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features. Blood 2003;102:1035-41.
34. Boonstra JG, van Lom K, Langerak AW, Graveland WJ, Valk PJ, Kraan J, van 't Veer MB, Gratama JW. CD38 as a prognostic factor in B cell chronic lymphocytic leukemia (B-CLL): comparison of three approaches to analyze its expression. Cytometry B Clin Cytom 2006;70:136-41.
35. Höglund M, Sehn L, Connors JM, Gascoyne RD, Siebert R, Säll T, Mitelman F, Horsman DE. Identification of cytogenetic subgroups and karyotypic pathways of clonal evolution in follicular lymphomas. Genes Chromosomes Cancer 2004;39:195-204.
36. Novak U, Oppliger Leibundgut E, Hager J, et al. A high-resolution allelotype of B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100:1787-94.
37. Gaidano G, Hauptschein RS, Parsa NZ, Offit K, Rao PH, Lenoir G, Knowles DM, Chaganti RS, Dalla-Favera R. Deletions involving two distinct regions of 6q in B-cell non-Hodgkin lymphoma. Blood 1992;80:1781-7.
38. Crossen PE, Godwin JM, Heaton DC, Tully SM. Chromosome abnormalities in chronic lymphocytic leukemia revealed by cytochalasin B and Epstein-Barr virus. Cancer Genet Cytogenet 1987;28:93-100.
39. Ravoet M, Sibille C, Roufosse F, Duvillier H, Sotiriou C, Schandené L, Martiat P, Goldman M, Willard-Gallo KE. 6q- is an early and persistent chromosomal aberration in CD3-CD4+ T cell clones associated with the lymphocytic variant of hypereosinophilic syndrome. Haematologica 2005;90:753-65.
40. Haslinger C, Schweifer N, Stilgenbauer S, Döhner H, Lichter P, Kraut N, Stratowa C, Abseher R. Microarray gene expression profiling of B cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. J Clin Oncol 2004;22:3937-49.
41. Zhang Y, Matthiesen P, Harder S, et al. A 3-cM commonly deleted region in 6q21 in leukemias and lymphomas delineated by fluorescence in situ hybridization. Genes Chromosomes Cancer 2000;27:52-8.
42. Han T, Ozer H, Sadamori N, Emrich L, Gomez GA, Henderson ES, Bloom ML, Sandberg AA. Prognostic importance of cytogenetic abnormalities in patients with chronic lymphocytic leukemia. N Engl J Med 1984;310:288-92.
43. Sellmann L, Scholtysik R, Kreuz M, et al. Gene dosage effects in chronic lymphocytic leukemia. Cancer Genet Cytogenet 2010;203:149-60.
44. Zhang L, Znoyko I, Costa LJ, Conlin LK, Daber RD, Self SE, Wolff DJ. Clonal diversity analysis using SNP microarray: a new prognostic tool for chronic lymphocytic leukemia. Cancer Genet 2011;204:654-65.
45. Jaglowski SM, Ruppert AS, Heerema NA, et al. Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukemia. Br J Haematol 2012;159:82-7.